MedPath

Ascidian Therapeutics, Inc.

Ascidian Therapeutics, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2020-01-01
Employees
11
Market Cap
-
Website
https://www.ascidian-tx.com

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Phase 1
Recruiting
Conditions
Stargardt Disease
Cone Rod Dystrophy
Juvenile Macular Degeneration
Stargardt Disease 1
Interventions
First Posted Date
2024-06-21
Last Posted Date
2025-07-01
Lead Sponsor
Ascidian Therapeutics, Inc
Target Recruit Count
13
Registration Number
NCT06467344
Locations
🇺🇸

University of San Francisco, San Francisco, California, United States

🇺🇸

Vitreo Retinal Associates, Gainesville, Florida, United States

🇺🇸

Bascom Palmer Eye Institute, Miami, Florida, United States

and more 7 locations

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials

Recruiting
Conditions
Cone Rod Dystrophy
Juvenile Macular Degeneration
Stargardt Disease
Stargardt Disease 1
First Posted Date
2024-06-06
Last Posted Date
2025-05-14
Lead Sponsor
Ascidian Therapeutics, Inc
Target Recruit Count
50
Registration Number
NCT06445322
Locations
🇺🇸

University of San Francisco, San Francisco, California, United States

🇺🇸

Vitreo Retinal Associates, Gainesville, Florida, United States

🇺🇸

Wilmer Eye Institute at John Hopkins, Baltimore, Maryland, United States

and more 5 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.